Study Watch with Irregular Pulse Monitor vs Impala

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Verily Life Sciences
VS
by AliveCor

AI Verdict

These tools are adjacent in their comparability, both focusing on cardiac monitoring with AI. Tool A, the Verily Study Watch, is a wearable designed for continuous, single-channel ECG monitoring and irregular pulse detection, primarily for clinical research and long-term data collection. In contrast, Tool B, AliveCor's Impala, is a portable 12-lead ECG device for rapid, diagnostic-quality cardiac assessments by healthcare professionals, including the detection of acute conditions like heart attacks.

Choose Study Watch with Irregular Pulse Monitor if…

Choose the Verily Study Watch if you require continuous, long-term physiological data collection for clinical research, particularly for conditions like atrial fibrillation or Parkinson's disease, where unobtrusive, real-world monitoring is crucial. Its design prioritizes continuous data capture with a long battery life and is ideal for large observational studies and investigational use in professional healthcare settings.

View Study Watch with Irregular Pulse Monitor →

Choose Impala if…

Choose AliveCor's Impala if you need a portable, AI-powered 12-Lead ECG device for rapid cardiac assessment in acute or emergency settings. Its reduced leadset and AI technology are designed for quick and efficient detection of life-threatening cardiac conditions, making it suitable for healthcare professionals requiring immediate diagnostic-quality ECGs.

View Impala →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Study Watch with Irregular Pulse Monitor Impala
Pricing Contact for pricing Contact for pricing
Deployment Device-based (wrist-worn watch) Portable device, integrated with mobile applications/platforms.
FDA Status True AI-estimated 1 AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Study Watch with Irregular Pulse Monitor

The Verily Study Watch is designed for continuous, unobtrusive monitoring with a long battery life, blending into daily life and requiring minimal patient interaction beyond initial setup and prompted ECG acquisitions. AliveCor's Impala, while portable, requires active placement of electrodes for each 12-lead ECG acquisition, which may be more involved for the user.

Clinical Value

Impala

AliveCor's Impala offers a portable 12-Lead ECG, providing a more comprehensive diagnostic picture for healthcare professionals to detect life-threatening cardiac conditions, including heart attacks. The Verily Study Watch primarily focuses on single-channel ECG recording and irregular pulse monitoring for atrial fibrillation, which is valuable but less comprehensive for acute diagnostics.

Pricing & Value

Tie

Both tools require contacting the company for pricing details, making a direct comparison of their cost-effectiveness difficult. Both are prescription-only devices intended for professional use, suggesting a similar sales model rather than direct-to-consumer pricing. Without transparent pricing, it's impossible to determine which offers better value.

Enterprise Readiness

Study Watch with Irregular Pulse Monitor

The Verily Study Watch is explicitly designed for clinical research and investigational use, supporting continuous data capture, configurable firmware, and integration with Verily's cloud server for HCP review. This indicates a robust infrastructure for large-scale data collection and management in enterprise settings. AliveCor's Impala is a portable device for healthcare professionals, but its enterprise integration capabilities are not as extensively detailed in the provided information.

Innovation

Tie

Both tools demonstrate innovation in their respective approaches. Verily's Study Watch innovates with its continuous, unobtrusive monitoring for research and irregular pulse detection, leveraging a wearable form factor for long-term data collection. AliveCor's Impala is innovative in providing a portable, AI-powered 12-Lead ECG with a reduced leadset, simplifying a traditionally complex procedure for rapid cardiac assessment.

Support & Docs

Tie

Both companies provide user manuals and support resources for their devices. AliveCor offers user manuals and customer support via phone and email. Verily's Study Watch, being prescription-only and geared towards clinical research, implies comprehensive support and documentation for healthcare professionals and researchers, though specific details on publicly available support channels are less explicit than AliveCor's.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Study Watch with Irregular Pulse Monitor Impala
Device Name Study Watch with Irregular Pulse Monitor Impala
Company Verily Life Sciences AliveCor
Key ECG Capability Single-channel ECG recording, irregular pulse monitoring Portable 12-Lead ECG acquisition
Target User/Setting Adult patients (22+) for clinical research and professional healthcare settings Healthcare professionals for rapid cardiac assessment
Specialties Cardiology, Family Medicine, Internal Medicine Cardiology, Emergency Medicine

Videos

Demos, reviews, and walkthroughs featuring Study Watch with Irregular Pulse Monitor and Impala.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The Verily Study Watch is designed for use in clinical research and healthcare settings, with Verily working to integrate various health data, including EHRs. AliveCor's Impala offers EHR integration, allowing ECGs to be automatically pulled into systems like GE Healthcare's MUSEu2122 NX, streamlining the workflow for physicians.
The Verily Study Watch is FDA-cleared for single-channel ECG recording and irregular pulse monitoring for atrial fibrillation, with studies confirming its ability to accurately detect AFib episodes. AliveCor's Impala is an AI-powered 12-Lead ECG device that acquires diagnostic-bandwidth leads and uses AI technology (KAIu2122 12L) for cardiac determinations, including detecting life-threatening cardiac conditions like heart attacks.
The Verily Study Watch is designed with an easy-to-use interface. AliveCor's Impala is a portable device designed for rapid cardiac assessment, and while specific learning curve data for Impala isn't detailed, other medical devices can have a learning curve, with some studies suggesting improvement over the first 24-25 cases.
Verily offers contact options for inquiries and information about their precision health platform. AliveCor provides an enterprise platform for healthcare professionals, offering deep, real-time analysis of heart rhythm data and seamless integration into existing workflows.
The Verily Study Watch is designed for scalable collection of rich and complex datasets across clinical and observational studies, and has been used in multi-year, multi-participant studies. AliveCor's solutions, including EHR integration and API/SDK offerings, are designed to integrate patient ECG data into various systems, which can facilitate multi-site data management.
The Verily Study Watch is prescription-only for adult patients (22+) to monitor irregular pulses for atrial fibrillation and is used in clinical research for conditions like Parkinson's disease and heart failure. AliveCor's Impala is a portable 12-Lead ECG for healthcare professionals, designed for rapid cardiac assessment and detection of life-threatening cardiac conditions, suitable for physician offices, minute clinics, and remote locations.

Backers

Who funded each tool's parent company.

Study Watch with Irregular Pulse Monitor

AI Tool Finder
AI-powered search. Results may not be comprehensive.